Abstract
INTRODUCTION: Recently, the cancer genome medical system has been rapidly promoted in Japan, such as cancer related gene panel test as NCC oncopanel and Fonduation One being covered by insurance. At the same time, there is a great deal of attention now on hereditary tumor diseases caused by abnormalities in cancer-related genes and their medical treatment. Von Hippel-Lindau (VHL) disease and tuberous sclerosis (TSC) are one such hereditary tumor disease, and develop tumors in multiple organs such as kidney tumors and lung tumors as well as brain tumors. The University of Tokyo Hospital has been developing an in-hospital medical care system for VHL disease and TSC. [VHL disease] If VHL disease is diagnosed at an early stage and strives for early detection and treatment of tumor, it is said that the prognosis is not largely different from normal people. Therefore, our hospital opened a specialized outpatient for VHL disease from 2012, and has carried out genetic diagnosis of VHL disease and medical treatment based on it. [TSC] Recently, the use of Afinitor for SEGA was covered by insurance in Japan, and a system in which multiple departments involved in our hospital cooperated was established, and regular meetings were held to determine treatment policies. DISCUSSION: It was the development of genetic counseling system and multidisciplinary cooperation system that was important in any disease. Genetic counseling helps patients with illness and their families to genetically understand and adapt to illness. In the case of hereditary diseases, the practice of genetic counseling was very useful. In addition, since it is a disease involving multiple organs, close cooperation with other in-hospital clinics has been extremely useful for early detection and treatment of patient’s lesions.